Boehringer Ingelheim has received EU approval for its Viramune (nevirapine) prolonged-release once-daily formulation, indicated for the treatment of HIV-1 infection.

The approval is based on results from clinical trials that confirmed the therapeutic benefits of nevirapine when administered in a once-daily formulation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The VERxVE trial evaluated the antiviral efficacy and safety of once-daily nevirapine 400mg compared to twice-daily nevirapine 200mg.

The TRANxITION trial examined the efficacy and safety of switching virologically suppressed patients from nevirapine immediate-release 200mg twice-daily to nevirapine prolonged-release 400mg once-daily.

The antiviral efficacy of Viramune prolonged-release tablets was found to be non-inferior to the older, twice-daily immediate-release 200mg tablet, with a comparable safety and tolerability profile.

The Viramune 400mg once-daily tablet was approved by the US Food and Drug Administration (FDA) earlier this year.